Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obeticholic Acid in PBC Patients with Inadequate Response to UDCA
NCT06715319Phase 3Completed
- Sponsor
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
- Start
- Oct 2021
- Primary completion
- Oct 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of obeticholic acid in primary biliary cholangitis (PBC), sponsored by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.. Started Oct 2021; status: completed.
02
Drugs
obeticholic acid
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NCT06715319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06715319.